Reproducibility of the VISITAG SURPOINT™ Module in Clinical Experience​

Similar to the European VISTAX study,2 SURPOINT COA confirmed the reproducibility and generalizability of the clinical safety and effectiveness of the optimized VISITAG SURPOINT™ Module PVI workflow in patients with paroxysmal AF.​

Graphs comparing VISTAX and SURPOINT COA study results

 


Patient Inclusion and Exclusion Criteria1

Key Inclusion Criteria

  • ≥18 years old with paroxysmal AF and
  • ≥1 documented episodes within 1 year preceding enrollment
  • Failed/intolerance to ≥1 Class I/III AADs

Key Exclusion Criteria

  • Previous surgical or catheter ablation for AF
  • Documented left atrial thrombus
  • Left atrial size >50 mm
  • Left ventricular ejection fraction <40%
  • NYHA functional Class III/IV


Study Design and Patient Follow-Up1

Patient follow-up and failure mode diagram

Figure adapted from Di Biase et al. JACC Clin Electrophysiol. 2022;8(9):1077-1089 under the CC BY license​.


 


Achieved VISITAG SURPOINT™ Module Targets1

Most achieved VISITAG SURPOINT™ Module targets (10th–90th percentile) were between 299.6–561.6 and 290.3–442.7 in the anterior/ridge/superior segments and posterior/inferior segments, respectively.​

Diagram of achieved target values per pulmonary vein segment

Figure adapted from Di Biase et al. JACC Clin Electrophysiol. 2022;8(9):1077-1089 under the CC BY license.